Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
2(100.0%)
2Total
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02431650Phase 1Completed

Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent

Role: collaborator

NCT02431637Phase 1Completed

Experimental Falciparum Transmission to Anopheles

Role: collaborator

NCT01075386Completed

The Effects of the Endocrine System on Endometrial Cancer

Role: collaborator

All 3 trials loaded